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The heart possesses a remarkable inherent capability to adapt itself to a wide array of 
genetic and extrinsic factors to maintain contractile function. Failure to sustain its com-
pensatory responses results in cardiac dysfunction, leading to cardiomyopathy. Diabetic 
cardiomyopathy (DCM) is characterized by left ventricular hypertrophy and reduced dia-
stolic function, with or without concurrent systolic dysfunction in the absence of hyper-
tension and coronary artery disease. Changes in substrate metabolism, oxidative stress, 
endoplasmic reticulum stress, formation of extracellular matrix proteins, and advanced 
glycation end products constitute the early stage in DCM. These early events are fol-
lowed by steatosis (accumulation of lipid droplets) in cardiomyocytes, which is followed 
by apoptosis, changes in immune responses with a consequent increase in fibrosis, 
remodeling of cardiomyocytes, and the resultant decrease in cardiac function. The heart 
is an omnivore, metabolically flexible, and consumes the highest amount of ATP in the 
body. Altered myocardial substrate and energy metabolism initiate the development of 
DCM. Diabetic hearts shift away from the utilization of glucose, rely almost completely 
on fatty acids (FAs) as the energy source, and become metabolically inflexible. Oxidation 
of FAs is metabolically inefficient as it consumes more energy. In addition to metabolic 
inflexibility and energy inefficiency, the diabetic heart suffers from impaired calcium han-
dling with consequent alteration of relaxation–contraction dynamics leading to diastolic 
and systolic dysfunction. Sarcoplasmic reticulum (SR) plays a key role in excitation– 
contraction coupling as Ca2+ is transported into the SR by the SERCA2a (sarcoplasmic/
endoplasmic reticulum calcium-ATPase 2a) during cardiac relaxation. Diabetic cardio-
myocytes display decreased SERCA2a activity and leaky Ca2+ release channel resulting 
in reduced SR calcium load. The diabetic heart also suffers from marked downregulation 
of novel cardioprotective microRNAs (miRNAs) discovered recently. Since immune 
responses and substrate energy metabolism are critically altered in diabetes, the present 
review will focus on immunometabolism and miRNAs.
Keywords: obesity, insulin resistance, inflammation, cardiomyopathy, innate and adaptive immunity, glucose 
metabolism, fat metabolism, miRnA
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inTRODUCTiOn
Insulin deficiency and/or resistance and elevated plasma glucose 
level characterize diabetes, a chronic and progressive metabolic 
disorder. While type 1 diabetes mellitus (T1DM) accounts for 
5–10% of all cases of diabetes (1), type 2 diabetes mellitus (T2DM) 
accounts for the remaining ~90% of all cases of diabetes (2). As of 
2015, 415 million people across the globe have diabetes mellitus 
(DM) (www.diabetesatlas.org), which will cost 12% of all global 
health expenditures (accounting for $320 billion in the USA alone) 
(3). The International Diabetic Federation predicts that 552 mil-
lion people will suffer from diabetes by 2030. T2DM is recognized 
as an independent risk factor for heart failure (HF). Patients with 
T2DM have a greater probability of death in established HF; suffer 
from worse prognosis after myocardial infarction (MI) (4–8); and 
accounts for 5.2% of all deaths globally (9, 10). T2DM is strongly 
associated with obesity and sedentary lifestyle coupled with 
increasingly westernized diet (2, 11). Diabetic patients are also 
highly susceptible to diastolic dysfunction, ventricular hypertro-
phy, and decreased myocardial strain (12).
Rubler and colleagues initially reported diabetic cardiomyo-
pathy (DCM) from their observation of cardiac hypertrophy on 
post-mortem hearts from four diabetic patients who died of HF 
without cardiovascular disease, which was subsequently followed 
by various other studies (13–16). The Strong Heart Study, the 
Cardiovascular Health Study, and the Framingham Study revealed 
cardiac hypertrophy with compromised systolic and diastolic 
function in DCM patients (4, 17–19). Of note, diastolic dysfunc-
tion has been reported in diabetic hearts without hypertrophy 
(20–22). In fact, DCM starts with diastolic dysfunction in patients 
with T1DM or T2DM followed by systolic dysfunction (23–27). 
Rodent models of T1DM including streptozotocin (STZ)-treated 
(28) or alloxan-treated animals (29) and T2DM models such as 
Goto-Kakizaki rat (30), Zucker fatty rats, Zucker diabetic fatty rats, 
leptin-deficient ob/ob mice, and leptin receptor-deficient db/db 
mice consistently show the human DCM phenotypes (31–33). Of 
note, STZ- and alloxan-induced diabetes is characterized by myo-
cardial atrophy including loss of contractile proteins as opposed 
to cardiac hypertrophy in T2DM models (34–36). In addition, in 
T1DM animals, the progress of systolic dysfunction is positively 
correlated with the progress of the magnitude and duration of 
hyperglycemia (hypoinsulinemic/hyperglycemia → systolic dys-
function) (31, 35–38). By contrast, mouse models of T2DM are 
characterized by hyperinsulinemia, hyperglycemia (later stages), 
and hyperlipidemia (hyperinsulinemic/hyperglycemic → hyper-
trophy and diastolic dysfunction) (31, 39–41).
Autophagy is reduced in the mouse hearts of OVE26 (a trans-
genic model of insulinopenic diabetes) and STZ-induced diabetic 
mouse hearts (42–44). Metformin has been shown to prevent 
DCM by stimulating AMP-activated protein kinase (AMPK) 
activity and enhancing autophagic capacity (43).
Recently, DM is identified as a microRNA (miRNA)-related 
disease (45), and several diabetic complications are associated 
with differential expressions of various miRNAs (46). Further, 
miRNAs play a vital role in the regulation of metabolism (47) and 
since DM is a metabolic disease it is logical to examine the role 
of miRNAs in DM. Thus the present review will focus on altered 
metabolism of glucose and fatty acids (FAs) as well as immune 
responses in diabetes.
DeCReASeD GLUCOSe UPTAKe  
AnD MeTABOLiSM
The heart consumes about 6  kg of ATP, or ~20 times its own 
weight, per day (48) that comes from the breakdown of fat, carbo-
hydrate, protein, ketone bodies, or lactate. Of note, the amount of 
ATP in the heart is small (~10 mM, enough for only a few beats) 
compared with the demand (~10,000 times greater) (49). About 
95% of total energy is generated from oxidative phosphorylation 
of FAs and glucose (50–52). A dramatic metabolic shift takes place 
in diabetic heart, as they rely almost completely on FAs for their 
energy source. As for example, 46 atoms of oxygen are required 
to generate 105 molecules of ATP from oxidation of 1 molecule of 
palmitate. By contrast, oxidation of 1 molecule of glucose utilizes 
12 atoms of oxygen to generate 31 molecules of ATP. Therefore, 
oxidation of FAs consumes ~0.3 oxygen molecules more than 
glucose to generate each molecule of ATP. Thus, the diabetic 
heart suffers from metabolic inflexibility due to its reliance on 
FAs. The lack of insulin production in T1DM patients causes 
a dramatic decrease in cardiac glucose uptake (53, 54) where 
hyperglycemia increases glucose oxidation and mitochondrial 
generation of superoxide (55–57). Increased production of super-
oxide damages DNA and activates poly (ADP ribose) polymerase 
1 (PARP-1) (58), which mediates inflammation and fibrosis in 
liver (59). PARP-1 inhibition improves cardiac function (60) and 
prevents hyperglycemia-induced pathological processes (61). 
While decreased glucose transporter type 4 (Glut4) expression in 
T1DM animals causes decreased glucose uptake in cardiac and 
skeletal muscle (62, 63), glucose uptake is impaired in T2DM 
hearts by decreased expression and translocation of Glut4/Glut1 
(64, 65). Diabetic db/db mice show decreased glucose oxidation 
and increased reliance on FAs, indicating that insulin resistance 
is not responsible for metabolic switch (66–69). The high rate of 
FA oxidation in T2DM patients and rodents increases produc-
tion of acetyl CoA and NADH, resulting in activation of pyruvate 
dehydrogenase kinase 4 (PDK4). PDK4 is also activated by per-
oxisome proliferator-activated receptor alpha (PPARα), which 
is overexpressed in diabetic rodents (70–73). Activated PDK4 
inhibits pyruvate dehydrogenase complex, thereby preventing 
oxidation of pyruvate (74, 75) (Figure 1). In addition, increased 
accumulation of FAs and their derivatives fatty acyl CoA, diacylg-
lycerol, and ceramide activate protein kinase C, c-Jun N-terminal 
kinases, mammalian target of rapamycin, and inhibitor of κB 
kinase β with consequent decrease in insulin signaling (76–79).
inCReASeD FORMATiOn OF ADvAnCeD 
GLYCATiOn enD PRODUCTS (AGes)
In the diabetic heart, glucose forms covalent adducts with the 
plasma proteins through a non-enzymatic reaction between the 
free amino groups of proteins and carbonyl groups of reducing 
sugars, resulting in the formation of stable glycosylation products 
by Amadori rearrangement, which is called glycation (91–94). 
FiGURe 1 | Schematic diagram showing changes in cardiac metabolism in diabetic cardiomyopathy. In the diabetic heart, glucose oxidation is inhibited at 
multiple steps: (i) uptake of glucose is inhibited by reduced expression of glucose transporter Glut4 as well as by blunted translocation of Glut4 in response to insulin 
(64, 65); (ii) inhibition of hexokinase activity by fatty acids (FAs) resulting in reduced conversion of glucose to glucose-6-phosphate (80); (iii) inhibition of 
phosphofructokinase activity by FA, leading to reduced formation of fructose-1,6-bisphosphate by fructose-6-phosphate (69); (iv) inhibition of pyruvate 
dehydrogenase phosphatase activity by FA resulting in reduced pyruvate dehydrogenase (PDH) activity, which leads to reduced conversion of pyruvate to acetyl 
CoA. In the diabetic heart, PPARα expression is activated by increased FA uptake (81, 82). Activated PPARα upregulates PDH kinase 4 enzymes, which inhibits PDH 
resulting in reduced production of acetyl CoA (83–85). FA transporters CD36 and FA transport protein import FAs into the cell. After import, FAs can be stored as 
triacylglycerol (TAG) or converted to fatty acyl CoA by fatty acyl-CoA synthetase (FACS). Carnitine palmitoyltransferase 1 (CPT1) transfers the acyl group of fatty acyl 
CoA to carnitine, which then shuttles into the mitochondria by carnitine translocase (CT). PPARα activates transcription of CPT1 (86). In the matrix, CPT2 reconverts 
the acylcarnitine back into free carnitine and fatty acyl CoA (87), which is then converted to acetyl CoA that can be used in the tricarboxylic acid to produce 
adenosine triphosphate by β-oxidation. Diabetes upregulates mitochondrial generation of reactive oxygen species (57, 88, 89), which affects Ca2+ signaling (90).
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Glycated proteins undergo a series of oxidation, dehydration, 
and cyclization reactions to form long-lived AGEs (95, 96). 
Both AGE and its receptor RAGE are overexpressed in diabetes 
(97) leading to the generation of reactive oxygen species (ROS) 
and subsequent activation of RAS–MAP kinase pathway (98). 
Activation of RAS–MAPK pathway in turn activates NF-κB 
pathway resulting in decreases in contractile proteins such as 
α-actin and myosin ATPase activity (35, 36) and shifts in myosin 
heavy chain isoforms from α to β with consequent develop-
ment of decreased systolic tension (36–38, 97, 99). In diabetes, 
increased serum levels of AGEs show positive correlation with 
ventricular isovolumetric relaxation time, arterial stiffness, 
and carotid intimal thickness (100–102). Treatment of diabetic 
animals with aminoguanidine (an inhibitor of AGE formation) 
(103, 104) or with alagebrium (ALT-711; disrupts AGE cross-link) 
(105) restored LV function and reduced myocardial collagen, 
highlighting the importance of AGE in cardiac dysfunction. AGEs 
also impair collagen degradation by matrix metalloproteinases 
(MMPs), such as MMP2, resulting in increased fibrosis (106, 
107). Fibrosis increases myocardial stiffness and impairs diastolic 
function (104). In T1DM heart, AGEs also induce cross-linking 
of SERCA2a pump, thereby attenuating sarcoplasmic reticulum 
(SR) Ca2+ reuptake (108, 109) with consequent attenuation of the 
maximum and minimum rate of pressure change in the ventricle 
and LV developed pressure (108). Of note, the type 2 ryanodine 
receptor-dependent Ca2+ release not only plays critical roles for 
4Mishra et al. Diabetes, Cardiomyopathy, and Immunometabolism
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excitation–contraction coupling in cardiomyocytes but plays 
crucial roles in the regulation of insulin secretion and glucose 
homeostasis (110, 111). Genetic ablation of the RAGE gene 
improves hemodynamic dysfunction, thereby providing AGE/
RAGE pathway as a potential therapeutic target to alleviate 
cardiac dysfunction in diabetes.
inCReASeD FA UPTAKe AnD 
MeTABOLiSM
The heart has a limited capacity for de novo synthesis of FAs. 
Therefore, it relies heavily on the circulating FAs (112). FAs trans-
locate from blood to cardiomyocytes using three FA transporters: 
cluster of differentiation 36 (CD36), FA transport protein 1, and 
the plasma membrane form of FA-binding protein (113–116). 
Increased PPARα expression in diabetic hearts (70–73, 117) aug-
ments transcription of FA transporters. About 75% of the trans-
located FAs are transferred to mitochondria for the generation of 
ATP and the rest are converted to triacylglycerol (TAG) for future 
use (118). Translocated FAs are activated by esterification to fatty 
acyl CoA by the action of cytosolic fatty acyl-CoA synthetase 
(FACS). Carnitine palmitoyltransferase 1 (CPT1) exchanges 
the CoA moiety of fatty acyl CoA for carnitine resulting in the 
formation of acylcarnitine. Acylcarnitine is transported across 
the inner mitochondrial membrane into the matrix by carnitine– 
acylcarnitine translocase. PPARα augments transcription of CPT1 
(119, 120). In the matrix, CPT2 reconverts the acylcarnitine back 
into free carnitine and fatty acyl CoA. PPARα increases transcrip-
tion of CPT2 (120). Fatty acyl CoA is then converted to acetyl 
CoA for β-oxidation and generation of ATP. PPARα increases 
conversion of fatty acyl CoA in the mitochondrial matrix to 
acetyl CoA. Thus, PPARα plays critical roles in metabolic repro-
graming in diabetic hearts.
Since the diabetic heart relies on FAs for ATP generation, it 
consumes ~30% more oxygen compared with non-diabetic heart 
to generate similar levels of ATP (87, 121) and generate the same 
or the reduced amounts of contractile force (41). This dis-
proportionate use of FAs also alters cellular ATP shuttling as 
long-chain acyl CoA derivatives inhibit the adenine nucleotide 
translocator for the transport of ATP from mitochondria to the 
cytosol (122–124), eventuating in inefficient delivery of ATP to 
myofibrils that affects cardiac contractility.
inFLAMMATiOn, innATe, AnD ADAPTive 
iMMUne ReSPOnSeS
Metabolic disturbances induce subcellular low-grade inflamma-
tion in the heart (125). Inflammation is a key pathogenic feature 
of lipid excess and diabetes. The innate immune system com-
prising of neutrophils, dendritic cells, macrophages, mast cells, 
and eosinophils also induces chronic metabolic inflammation 
(126, 127). Myocardial inflammation is implicated in the 
development of DCM (128–131). Nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB), a primary regula-
tor of inflammatory responses, is activated in the heart upon 
exposure to FAs or glucose (132, 133). NF-κB induces not only 
the expression of pro-inflammatory cytokines, such as tumor 
necrosis factor alpha (TNFα), interleukin 6 (IL6), pro-IL1β, and 
pro-IL18, but it also induces the expression of NLR family pyrin 
domain-containing 3 (NLRP3) inflammasome (134). Activated 
RAGE also triggers an inflammatory response by heterodi-
merizing with TLR-4 leading to the production of pro-IL1β, 
Pro-IL18, and NLRP3 (135). Activated NLRP3 inflammasome 
activates caspase-1 and mediates the processing and release of 
pro-inflammatory cytokines IL1β and IL18 resulting in inflam-
matory cell infiltration and amplification of the inflammatory 
response (125, 136–138). Likewise, depletion of NLRP3 attenu-
ates inflammation and cardiomyopathy in T2DM rats (137). Of 
note, activated inflammasomes play critical roles in the patho-
genesis of HF (139). Resident immune cells in the resting heart 
include the following: macrophages, residing near endothelial 
cells or within the interstitial space (140–143); mast cells that 
are responsible for early triggers of immune responses (144); a 
small number of adaptive immune cells: B cells and regulatory 
T (TReg) cell subsets (142, 145, 146); and dendritic cells that test 
sample antigens (142, 147) (Figure 2A). The differential expres-
sion of major histocompatibility complex (MHC) class II and 
CC chemokine receptor 2 (CCR2) distinguishes three different 
subsets of cardiac macrophages: MHC class IIhigh (CCR2−), MHC 
class IIlow (CCR2−), and CCR2+ macrophages. The first two 
are the preponderant macrophages in the heart, derived from 
embryogenic progenitors and renewed through in situ prolifera-
tion, rather than through monocyte input. By contrast, CCR2+ 
macrophages derive from and replenished by circulating blood 
monocytes, which comprise of Ly6Chigh and Ly6Clow (148–150). 
Studies in Ccr2 knockout mice (lacking circulating monocytes) 
reveal increased cardiac pathology (151, 152). The loss of 
Ly6Chigh monocytes prevents hypertension-induced cardiac 
fibrosis and improves cardiac function after MI (141, 153, 154). 
Monnerat et al. suggest that diabetes enhances IL1β production 
from cardiac MHC IIhigh pro-inflammatory macrophages through 
activation of TLR2–NLRP3 inflammasome axis (155). The 
increased level of IL1β leads to a reduction in potassium current 
and an increase in calcium sparks in cardiomyocytes, which cause 
cardiac arrhythmias (156). By contrast, M2-like macrophages 
(CD206+F4/80+CD11b+) exert profound functions on tissue 
repair in heart depending on IL4 secretion (156). Recent stud-
ies implicate TNFβ producing B cells as a major contributor to 
myocardial fibrosis (153, 157). Antigen and cytokine stimulation 
are known to differentiate naive T cells into distinct T cell sub-
populations that include T helper cells and CD4+CD25+FOXP3+ 
TReg cells (158). TReg cells comprise a subset of CD4+ lymphocytes 
that suppress activation, proliferation, and effector responses of 
both innate and adaptive immune cells (159–161). As opposed 
to B cells, depletion of TReg cells aggravates myocardial fibrosis 
and adoptive transfer of exogenous TReg cells into these mice 
attenuates the extent of myocardial fibrosis (158). The following 
pro-inflammatory changes with oxidative stress and decreased 
cardiac function were detected in STZ-induced rat model of 
T1DM (162): (i) significant increases in myocardial intercellular 
adhesion molecule 1 and vascular cell adhesion molecule 1, (ii) 
increased expression of beta2-leukotrienes-integrins+ (CD18+, 
CD11a+, CD11b+), (iii) increased expression of TNFα, and 
AB
FiGURe 2 | (A) Schematic diagram showing immune cells in the healthy heart. Macrophages are the preponderant immune cells in the resting heart and reside 
primarily surrounding endothelial cells and also in the interstitium among cardiomyocytes (141–143). The less preponderant immune cells include the following: mast 
cells, dendritic cells, B cells, and regulatory T (TReg) cells (142, 144, 147). Neutrophils and monocytes, in general, are not detected in the resting heart. (B) Schematic 
diagram showing infiltration of neutrophils and monocytes from the circulation and their effects on resident immune cells in the diabetic cardiomyopathy (DCM) heart. 
In DCM, activated B cells release CCL7 that activates blood monocytes (146). Upon infiltration activated monocytes stimulate mast cells to release histamine, TNF, 
and interleukin 1β (IL1β), which activate neutrophils in circulation (144, 174). Activated neutrophils infiltrate heart and activate mast cells through damage-associated 
molecular patterns as well as blood neutrophils. Activated monocytes secrete TGFβ, which activates fibroblasts to induce formation of collagen.
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(iv) IL1β (Figure  2B). Treatment of STZ-induced DCM rats 
with irbesartan (AT-1 receptor antagonist) has been reported 
to improve cardiac functions by attenuating cardiac inflamma-
tion (IL1β, TNFα, and TGFβ) and restoration of MMP activity 
with consequent decrease in fibrosis (107). Similar results were 
reported after neutralization of TNFα (163) or genetic deletion 
of neurokinin receptor B (164) in rodent models of T1DM. 
Subsequently, several studies confirmed the pro-inflammatory 
phenotypes in diabetic rodent heart (165–167). As opposed to 
metabolic responses, immune responses in T1DM and T2DM 
are comparable as both of them show consistent activation of 
pro-inflammatory transcription factor NF-κB. Cytokines (i) 
increase formation of peroxynitrite, which play critical roles in 
cardiac dysfunction (168), (ii) exert direct effects on the function 
of SR as well as on the regulation of SR calcium ATPase expres-
sion (168, 169), and (iii) increase fibrosis (170). Treatment of rats 
and humans with statins (171), renin angiotensin aldosterone 
system (RAAS) inhibitors (107), metformin (172), and thiazoli-
dinediones (173) reduces inflammation in the heart and improve 
cardiac function.
miRnA in DiABeTiC HeARTS
MicroRNAs are highly conserved endogenous small non-coding 
RNAs, ~22 nucleotides in length, that regulate gene expression by 
binding to partially complementary sequences of mRNA (175). 
The failing hearts consistently show chronic immune activation 
and aberrant miRNA expression (176). Thus, miR-155 plays an 
important role in the mammalian immune systems as well as dur-
ing HF and is abundantly expressed in T-cells, B-cells, and mono-
cytes (177–180). miRNAs are also differentially expressed during 
HF (181). STZ-induced diabetic heart expresses higher levels of 
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miR-195 and silencing of miR-195 reduces DCM (182). Likewise, 
miR-141 is increased in diabetic heart and affects mitochondrial 
function and ATP generation (183). Palmitate-stimulated neo-
natal rat cardiomyocytes (NRCs) and diet-induced obese (DIO) 
mouse heart also showed increased expression of miR-451, which 
decreases LKB1/AMPK signaling (184). Expression of miR-133a 
reduces Glut4 expression with consequent decrease in insulin-
mediated glucose uptake in NRCs (185). While overexpression of 
miR-223 in NRCs significantly increased glucose uptake by increas-
ing total Glut4 level and its translocation, inhibition of miR-223 
in the heart resulted in a significant decrease in Glut4 expression 
(186). In contrast to the findings in NRCs, expression of miR-133a 
is decreased in the hearts of diabetic mice and is associated with 
increased fibrosis. Of note, overexpression of miR-133a in the heart 
attenuates cardiac fibrosis (187). Murine miR-322 has recently 
been shown to provide cardioprotection against consequences of 
hyperinsulinemia and hyperlipidemia (188). In Ins+/– Akita mice, 
a model for T1DM, the majority of miRNAs are downregulated in 
the heart (189), including miR-133a which regulates contractility 
of the diabetic heart (190). Even after treatment with insulin, which 
normalizes blood glucose levels, there are several miRNAs that 
remain differentially regulated in the diabetic heart, and they can 
potentially contribute to pathological remodeling of the diabetic 
heart (191). These miRNAs could be a potential target for develop-
ing a novel therapeutic strategy for the treatment of diabetic HF.
Diabetes mellitus is a metabolic disease, and miRNAs play a 
crucial role in the regulation of metabolism (47). Increased levels 
of plasma cholesterol and triglyceride are common in diabetes, 
and liver specific ablation of miR-122, the most abundant miRNA 
in the liver, reduces plasma cholesterol and triglyceride levels 
(192, 193). The intracellular cholesterol and FA homeostasis are 
controlled by miR-33a and miR-33b, which target genes involved 
in cholesterol export including adenosine triphosphate-binding 
cassette transporters (194–196). Endogenous inhibition or 
knockout of miR-33 leads to increased plasma high-density lipid 
levels (194–197). MiR-223 controls the expression of Glut4 gene 
in cardiomyocytes, and miR-223 is upregulated while Glut4 is 
downregulated in human diabetic hearts (186). The switch of gly-
colysis to FA oxidation is regulated by PPARδ, which is regulated 
by the miR-199/miR-214 cluster. The miR-199/miR-214 cluster 
downregulates PPARδ and impairs FA oxidation (198). ROS 
stimulates apoptosis by mitochondrial cytochrome c release and 
ceramide generation (199). In rat cardiomyocytes, high glucose 
upregulates miR-34a and miR-1 that reduces the levels of B-cell 
lymphoma 2 (Bcl-2) and insulin-like growth factor 1 (Igf-1) 
genes, respectively, and induces apoptosis (200, 201). Recently, 
Kuwabara et  al. has elegantly shown that miR-451 plays a key 
role in exacerbating lipotoxicity in cardiac myocytes and high-fat 
diet-induced cardiac hypertrophy in mice through suppression of 
the LKB1/AMPK pathway (184). MiR-133a, the most abundant 
miRNA in the heart, is downregulated in the diabetic mice heart 
with consequent induction of cardiac hypertrophy (202) and 
fibrosis (187). Lack of miR-133a also causes contractile dysfunc-
tion in the diabetic mice heart (190). These changes cause dias-
tolic dysfunction, which if untreated leads to potential systolic 
dysfunction (28).
COnCLUSiOn AnD FUTURe 
PeRSPeCTiveS
Cardiovascular disease has remained the leading cause of mortality 
and morbidity in individuals with diabetes. DCM is emerging as 
an increasing health concern with the epidemic rise in DM world-
wide. Animal studies have clearly shown that glycemic control at 
an early stage prevents the development of DCM, and that certain 
anti-diabetic drugs exert anti-remodeling effects. While a large 
body of epidemiological evidence (50,000 T2DM patients) indicate 
a positive correlation between blood glucose level and/or HbA1c 
and the risk of HF (203–205), a meta-analysis of randomized 
controlled trials (37,229 patients) showed no effect of intensive 
glycemic control on the risk of HF in T2DM patients (206).
Therapeutic approach for DCM depends mainly on (i) gly-
cemic control, (ii) glucose-lowering drug administration, (iii) 
improvement of autophagy, and (iv) an active life style. Earliest 
detection, helped by current research on miRNAs, will enhance 
therapeutic efficacy. The current burst of scientific evidence for 
the potential use of circulating miRNAs as biomarkers for car-
diomyopathy is generating hopes that someday soon detection of 
specific miRNAs in biofluids of patients will help early treatment 
of both diabetes and cardiomyopathy.
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